Drug intelligence / Profile preview

monovalent rAT

Development stage
Unknown
Lead developer
Henry M. Jackson Foundation for the Advancement of Military Medicine
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Monovalent rAT is a recombinant protein subunit vaccine candidate developed by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF). It consists of a detoxified version of the Staphylococcus aureus alpha-hemolysin (alpha-toxin, Hla), which is a critical virulence factor that forms pores in host cell membranes, leading to cell death and tissue damage. The vaccine is designed to stimulate the production of neutralizing antibodies that bind to and inactivate the alpha-toxin, thereby preventing or reducing the severity of S. aureus infections, including skin and soft tissue infections and invasive disease. It has been evaluated in Phase 1/2 clinical trials as both a standalone monovalent vaccine and as a component of a bivalent formulation alongside rLukS-PV.

Other names
rAT vaccinerecombinant alpha-toxin vaccineStaphylococcus aureus alpha-toxin toxoid
02

Targets

Hla (Staphylococcus aureus alpha toxin)

Beyond the preview

Go deeper on monovalent rAT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on monovalent rAT.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call